Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.2556
- Book/Share 19.1229
- PB 4.0236
- Debt/Equity 0.7209
- CurrentRatio 1.4103
- ROIC 0.2167
- MktCap 192947545200.0
- FreeCF/Share 6.7321
- PFCF 11.3239
- PE 11.1553
- Debt/Assets 0.3027
- DivYield 0.0411
- ROE 0.3816
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=140454&wire=1 or contact Joseph E. Levi, Esq.
Read More
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: April 02, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , April 2, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Merck & Co., Inc. ("Merck" or "the Company") (NYSE: MRK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022, and February 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=140221&wire=1 or contact Joseph E. Levi, Esq.
Read More
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Published: April 01, 2025 by: CNBC
Sentiment: Positive
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit – MRK
Published: April 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025.
Read More
Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=140201&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Published: April 01, 2025 by: CNBC Television
Sentiment: Negative
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.
Read More
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK
Published: March 31, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=140025&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Published: March 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=139205&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=139197&wire=1 or contact Joseph E. Levi, Esq.
Read More
TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Investors who lost money on Merck & Co., Inc. (MRK) should contact Levi & Korsinsky about pending Class Action - MRK
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.
Read More
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , March 27, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co ("Merck" or the "Company") (NYSE: MRK). IF YOU SUFFERED A LOSS ON YOUR MERCK INVESTMENTS, CLICK HERE BEFORE APRIL 14, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE:MRK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period").
Read More
Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact The Gross Law Firm
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Forget S&P 500 And Buy These Dividend Icons Instead
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Positive
The S&P 500's high valuation and low yield make it unappealing for value and income investors. In this article, I highlight 2 durable dividend stocks that support far higher yields that are well-supported by cashflows. Both have long track records of raising their payouts and are far more attractively valued than the S&P 500.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. (“Merck” or the “Company”) (NYSE: MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE:MRK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period").
Read More
European Commission (EC) Approves Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
Published: March 26, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--European Commission (EC) Approves Merck's CAPVAXIVE® for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults.
Read More
Merck & Co., Inc. Class Action: Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK
Published: March 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=138695&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
Published: March 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=138481&wire=1 or contact Joseph E. Levi, Esq.
Read More
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE:MRK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period").
Read More
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, today announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China. “Elevate.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert M. Davis J.D.
- Employees 73000